Sant Pau - Institut de Recerca

Main lines of research

Investigation of the genetic basis of venous and arterial thrombosis. GAIT-1 andGAIT-2 projects.
Investigation of new antithrombotic drugs: thrombin inhibitors, molecules against activated factor X, low molecular weight heparin with oral activity, among others.
Biomarkers of prothrombotic states in patients under 55 years with venous thromboembolic disease, acute ischaemic stroke, or acute myocardial infarction. VEREMA project.
Applied clinical development of the self-management model of oral anticoagulant treatment.
Mathematical models of prediction of the individual risk of thromboembolic disease. RETROVE and PAN projects.
CITA project. Centre for Antithrombotic Therapy Management. Research into a new ambulatory management model for patients receiving any kind of antithrombotic therapy (anti vitamin-K, new oral anticoagulants, low molecular weight heparins, antiplatelets) by incorporating new educational programmes, specialized nursing and new communication technologies.

Challenges

Study QTL detected in GAIT-1 families in relation to phenotypes of haemostasis with thrombosis risk (resistance to activated protein C, factor VIII, homocysteine, factor XII, body mass index and others).
Replicate QTL related to thrombosis in GAIT-1 families by means of the linkage analysis using new GAIT-2 families.
Conduct genome-wide association study (GWAS) of phenotypes involved in GAIT-1.
GWAS of phenotypes included in GAIT-2.
Analyse RNA expression in the GAIT-2 families.
Investigate miRNA associated with thromboembolic disease in GAIT-2.
Complete recruitment for the RETROVE project.
Recruit team for the MIRTO project (Modelling Individual Risk of Thrombosis in Oncology), with the goal of establishing an individual risk score for venous thromboembolism (RETROVO sub-project) and for ischaemic stroke (SINO subproject) in patients with cancer.
Research plasma proteins associated with the risk of venous thromboembolism by using high affinity proteomics developed
at Karolinska Institutet. VEREMA project, joint collaboration between the European case-control studies VEBIOS (Sweden), RETROVE (from our unit) and MARTHA (France).
Continue collaboration with the RCV Spanish cardiovascular patient network and with other European groups, mainly with the goal of applying GAIT project findings to cohorts of patients with venous and arterial thrombosis in Spain and other European countries.
Evaluate the effectiveness of an educational programme for patients taking antiplatelet therapy (aspirin and/or clopidogrel) in reducing severe complications: EDUCANT clinical trial.

Group coordination

SOUTO ANDRES, JOAN CARLES FGS
jsouto@santpau.cat

Members

Acosta Isaac, Francisco Rene FGS
Bercianos Repes, Elaia IR
Carrasco Exposito, Marina FGS
Llobet Lorente, Maria Dolors FGS
Mateo Arranz, Jose FGS
Millon Caño, Juan Antonio FGS
Mojal Garcia, Sergio IR
Moret Puig, Carla FGS
Romero Roman, Lidia FGS
Tirado Garcia, Isabel FGS
Vilalta Seto, Noelia FGS

Publications 2022

(JIF 2022)

Canyelles M, Plaza M, Rotllan N, Llobet D, Julve J, Mojal S, Diaz M, Soria JM, Escola JC, Tondo M, Blanco F, Souto JC. TMAO and Gut Microbial-Derived Metabolites TML and gamma BB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine. 2022; 11(5):1425. DOI:10.3390/jcm11051425. PMID:35268516. IF:3,9 (Q2/4D). Document Type: Article.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document Type: Article.
Corrochano M, Acosta R, Plaza M, Muñoz R, Mojal S, Moret C, Souto JC. Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. PLoS One. 2022; 17:e0278693. DOI:10.1371/journal.pone.0278693. PMID:36490245. IF:3,7 (Q2/4D). Document Type: Article.
Cruz R, Diz S, Lopez-de Heredia M, Quintela I, Ceballos FC, Lorenzo GM, Gonzalez R, Gago M, Porras MS, Castano J, Nevado J, Aguado JM, Aguilar C, Aguilera S, Almadana V, Almoguera B, Alvarez N, Andreu A, Arana E, Arango C, Arranz MJ, Artiga MJ, Baptista RC, Barreda M, Belhassen M, Bezerra JF, Bezerra M, Boix L, Brion M, Brugada R, Bustos M, et al. [Martinez-Perez A, Soria JM, Souto JC, Fernandez-Cadenas I]. Novel genes and sex differences in COVID-19 severity. HUMAN MOLECULAR GENETICS. 2022; 31(22). DOI:10.1093/hmg/ddac132. PMID:35708486. IF:3,5 (Q2/4D). Document Type: Article.
Gil AD, Suarez GMG, Puig CM, Ganoza AH. Superwarfarin poisoning: challenges still remain. Bmj Case Reports. 2022; 15(5):e248385. DOI:10.1136/bcr-2021-248385. PMID:35584857. Document Type: Article.
Gonzalez JR, Mateo J, Gonzalez V, Marco P, Garcia V, Reverter JC, Lecumberri R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clinical & Translational Oncology. 2022; 24(5). DOI:10.1007/s12094-021-02735-1. PMID:34850351. IF:3,4 (Q3/6D). Document Type: Review.
Jimenez V, Alvarez MT, Bravo AP, Galmes BJ, Hernandez MDN, Hidalgo OB, Alonso CM, Gonzalez NFP, Coll J, Nunez R, Carrasco M, Candel FG, Gonzalez JR, Garcia CH, Castro MJV, Mir R. Clinical Efficacy and Safety of Fanhdi(R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 2022; 28:10760296221074348. DOI:10.1177/10760296221074348. PMID:35108125. IF:2,9 (Q3/6D). Document Type: Article.
Lopez S, Martinez A, Rodriguez A, Vinuela A, Brown AA, Martin L, Vilalta N, Arus M, Panousis NI, Buil A, Sabater M, Souto JC, Dermitzakis ET, Soria JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06). DOI:10.1055/s-0041-1742169. PMID:35272364. IF:6,7 (Q1/2D). Document Type: Article.
Megias JE, Boix SB, Moreno RB, Mingot ME, Lopez MR, Hirnyk MC, Arranz JM, Villas JMC, Guaita SH, Meda MM, Jaime FL, Albo C, Palomero A, Seto NV, Lecinena IL, Haro A, Andres JLP. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. THROMBOSIS RESEARCH. 2022; 216. DOI:10.1016/j.thromres.2022.06.001. PMID:35696967. IF:7,5 (Q1/2D). Document Type: Article.
Paramo JA, Lozano ML, Gonzaalez JR, Mateo J. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT). MEDICINA CLINICA. 2022; 158(2). DOI:10.1016/j.medcli.2021.05.020. PMID:34311973. IF:3,9 (Q2/4D). Document Type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document Type: Article.
Soto I, Mateo J, Garcia DA, Gil B, Ruiz E, Ivanova Y, Lorenzo TM, Maravilla P, Hidalgo A, Merino M. The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis. BMC HEALTH SERVICES RESEARCH. 2022; 22(1):115. DOI:10.1186/s12913-021-07447-4. PMID:35081958. IF:2,8 (Q3/6D). Document Type: Article.
Thibord F, Klarin D, Brody JA, Chen MH, Levin MG, Chasman DI, Goode EL, Hveem K, Teder M, Martinez-Perez A, Aissi D, Daian D, Ito K, Natarajan P, Lutsey PL, Nadkarni GN, de Vries PS, Cuellar G, Wolford BN, Pattee JW, Kooperberg C, Braekkan SK, Li RF, Saut N, Sept C, Germain M, Judy RL, Wiggins KL, Ko D, O’Donnell CJ, Taylor KD, Giulianini F, De Andrade M, et al. [Soria JM, Souto JC, Sabater M]. Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. CIRCULATION. 2022; 146(16). DOI:10.1161/CIRCULATIONAHA.122.059675. PMID:36154123. IF:37,8 (Q1/1D). Document Type: Article.

Publications 2021

Anaya R, Rodriguez M, Gil JM, Vilalta N, Merchan A, Moral V, Mateo J, Martinez MJ. Correlation between PlateletWorks(R) and PFA-100(R) for Measuring Platelet Function before Urgent Surgery in Patients with Chronic Antiplatelet Therapy. Journal of Clinical Medicine. 2021; 10(2):255. DOI:10.3390/jcm10020255. PMID:33445597. IF:4,964.
Goumidi L, Thibord F, Wiggins KL, Li RF, Brown MR, Vlieg AV, Souto JC, Soria JM, Ibrahim M, Saut N, Daian D, Olaso R, Amouyel P, Debette S, Boland A, Bailly P, Morrison AC, Mook DO, Deleuze JF, Johnson A, de Vries PS, Sabater M, Chiaroni J, Smith NL, Rosendaal FR, Chasman DI, Tregouet DA, Morange PE. Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. BLOOD. 2021; 137(17). DOI:10.1182/blood.2020008997. PMID:33512453. IF:25,476.
Koller T, Kinast N, Castellanos AG, Garcia SP, Iglesias PP, Vintro XL, Arranz JM, Seto NV, Garcia MVM, Moreno AB, Aznar J, Albaladejo GE, Diaz M. Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry. Scandinavian Journal of Trauma Resuscitation & Emergency Medicine. 2021; 29(1):57. DOI:10.1186/s13049-021-00867-5. PMID:33836790. IF:3,803.
Llobet D, Vallve C, Tirado I, Vilalta N, Carrasco M, Oliver A, Mateo J, Fontcuberta J, Souto JC. Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project. BLOOD COAGULATION & FIBRINOLYSIS. 2021; 32(2). DOI:10.1097/MBC.0000000000001006. PMID:33337623. IF:1,061.
Mingot ME, Pardos J, Haya S, Bastida JM, Tassies D, Marco A, Nunez R, Garcia F, De Mora MCFS, Soto I, Alvarez MT, Asenjo S, Carrasco M, Lluch R, Martin JM, Rodriguez A, Rosello E, Torres L, Marcellini S, Moreto A, Rodriguez JA, Aguinaco R, Alonso N, Cervero C, Fernandez N, Martinez MP, Perez M, Perez R, Rodriguez R, Uribe M, Caparros IS, et al. Management of acquired hemophilia A: results from the Spanish registry. Blood Advances. 2021; 5(19). DOI:10.1182/bloodadvances.2021004626. PMID:34521101. IF:7,637.
Perez A, Batlle J, Pinto JC, Corrales I, Borras N, Garcia I, Cid AR, Bonanad S, Parra R, Mingot ME, Navarro N, Altisent C, Perez R, Moreto A, Herrero S, Soto I, Mosteirin NF, Jimenez V, Jacob AD, Fontanes E, Mateo J, Quismondo NC, Batlle F, Vidal F, Lopez MF. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project. HAEMOPHILIA. 2021; 27(6). DOI:10.1111/hae.14405. PMID:34494337. IF:4,263.
Roman M, Benitez O, Canaro MI, Fernandez MFL, Jaime FLJ, Arranz JM, Nunez R, Lopez MR, Aisa CS, Jimenez V. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. EXPERT OPINION ON BIOLOGICAL THERAPY. 2021; 21(9). DOI:10.1080/14712598.2021.1932811. PMID:34225551. IF:5,589.

2017 Scientific Report – Thrombosis and Haemostasis

Introduction

Main lines of research

Investigation of the genetic basis of venous and arterial thrombosis. GAIT-1 andGAIT-2 projects.
Investigation of new antithrombotic drugs: thrombin inhibitors, molecules against activated factor X, low molecular weight heparin with oral activity, among others.
Biomarkers of prothrombotic states in patients under 55 years with venous thromboembolic disease, acute ischaemic stroke, or acute myocardial infarction. VEREMA project.
Applied clinical development of the self-management model of oral anticoagulant treatment.
Mathematical models of prediction of the individual risk of thromboembolic disease. RETROVE and PAN projects.
CITA project. Centre for Antithrombotic Therapy Management. Research into a new ambulatory management model for patients receiving any kind of antithrombotic therapy (anti vitamin-K, new oral anticoagulants, low molecular weight heparins, antiplatelets) by incorporating new educational programmes, specialized nursing and new communication technologies.

Challenges

Study QTL detected in GAIT-1 families in relation to phenotypes of haemostasis with thrombosis risk (resistance to activated protein C, factor VIII, homocysteine, factor XII, body mass index and others).
Replicate QTL related to thrombosis in GAIT-1 families by means of the linkage analysis using new GAIT-2 families.
Conduct genome-wide association study (GWAS) of phenotypes involved in GAIT-1.
GWAS of phenotypes included in GAIT-2.
Analyse RNA expression in the GAIT-2 families.
Investigate miRNA associated with thromboembolic disease in GAIT-2.
Complete recruitment for the RETROVE project.
Recruit team for the MIRTO project (Modelling Individual Risk of Thrombosis in Oncology), with the goal of establishing an individual risk score for venous thromboembolism (RETROVO sub-project) and for ischaemic stroke (SINO subproject) in patients with cancer.
Research plasma proteins associated with the risk of venous thromboembolism by using high affinity proteomics developed
at Karolinska Institutet. VEREMA project, joint collaboration between the European case-control studies VEBIOS (Sweden), RETROVE (from our unit) and MARTHA (France).
Continue collaboration with the RCV Spanish cardiovascular patient network and with other European groups, mainly with the goal of applying GAIT project findings to cohorts of patients with venous and arterial thrombosis in Spain and other European countries.
Evaluate the effectiveness of an educational programme for patients taking antiplatelet therapy (aspirin and/or clopidogrel) in reducing severe complications: EDUCANT clinical trial.

Team

Group coordination

SOUTO ANDRES, JOAN CARLES FGS
jsouto@santpau.cat

Members

Scientific output

Publications 2022

(JIF 2022)

Canyelles M, Plaza M, Rotllan N, Llobet D, Julve J, Mojal S, Diaz M, Soria JM, Escola JC, Tondo M, Blanco F, Souto JC. TMAO and Gut Microbial-Derived Metabolites TML and gamma BB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine. 2022; 11(5):1425. DOI:10.3390/jcm11051425. PMID:35268516. IF:3,9 (Q2/4D). Document Type: Article.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document Type: Article.
Corrochano M, Acosta R, Plaza M, Muñoz R, Mojal S, Moret C, Souto JC. Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. PLoS One. 2022; 17:e0278693. DOI:10.1371/journal.pone.0278693. PMID:36490245. IF:3,7 (Q2/4D). Document Type: Article.
Cruz R, Diz S, Lopez-de Heredia M, Quintela I, Ceballos FC, Lorenzo GM, Gonzalez R, Gago M, Porras MS, Castano J, Nevado J, Aguado JM, Aguilar C, Aguilera S, Almadana V, Almoguera B, Alvarez N, Andreu A, Arana E, Arango C, Arranz MJ, Artiga MJ, Baptista RC, Barreda M, Belhassen M, Bezerra JF, Bezerra M, Boix L, Brion M, Brugada R, Bustos M, et al. [Martinez-Perez A, Soria JM, Souto JC, Fernandez-Cadenas I]. Novel genes and sex differences in COVID-19 severity. HUMAN MOLECULAR GENETICS. 2022; 31(22). DOI:10.1093/hmg/ddac132. PMID:35708486. IF:3,5 (Q2/4D). Document Type: Article.
Gil AD, Suarez GMG, Puig CM, Ganoza AH. Superwarfarin poisoning: challenges still remain. Bmj Case Reports. 2022; 15(5):e248385. DOI:10.1136/bcr-2021-248385. PMID:35584857. Document Type: Article.
Gonzalez JR, Mateo J, Gonzalez V, Marco P, Garcia V, Reverter JC, Lecumberri R. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH-SETH. Clinical & Translational Oncology. 2022; 24(5). DOI:10.1007/s12094-021-02735-1. PMID:34850351. IF:3,4 (Q3/6D). Document Type: Review.
Jimenez V, Alvarez MT, Bravo AP, Galmes BJ, Hernandez MDN, Hidalgo OB, Alonso CM, Gonzalez NFP, Coll J, Nunez R, Carrasco M, Candel FG, Gonzalez JR, Garcia CH, Castro MJV, Mir R. Clinical Efficacy and Safety of Fanhdi(R), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 2022; 28:10760296221074348. DOI:10.1177/10760296221074348. PMID:35108125. IF:2,9 (Q3/6D). Document Type: Article.
Lopez S, Martinez A, Rodriguez A, Vinuela A, Brown AA, Martin L, Vilalta N, Arus M, Panousis NI, Buil A, Sabater M, Souto JC, Dermitzakis ET, Soria JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06). DOI:10.1055/s-0041-1742169. PMID:35272364. IF:6,7 (Q1/2D). Document Type: Article.
Megias JE, Boix SB, Moreno RB, Mingot ME, Lopez MR, Hirnyk MC, Arranz JM, Villas JMC, Guaita SH, Meda MM, Jaime FL, Albo C, Palomero A, Seto NV, Lecinena IL, Haro A, Andres JLP. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. THROMBOSIS RESEARCH. 2022; 216. DOI:10.1016/j.thromres.2022.06.001. PMID:35696967. IF:7,5 (Q1/2D). Document Type: Article.
Paramo JA, Lozano ML, Gonzaalez JR, Mateo J. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT). MEDICINA CLINICA. 2022; 158(2). DOI:10.1016/j.medcli.2021.05.020. PMID:34311973. IF:3,9 (Q2/4D). Document Type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document Type: Article.
Soto I, Mateo J, Garcia DA, Gil B, Ruiz E, Ivanova Y, Lorenzo TM, Maravilla P, Hidalgo A, Merino M. The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis. BMC HEALTH SERVICES RESEARCH. 2022; 22(1):115. DOI:10.1186/s12913-021-07447-4. PMID:35081958. IF:2,8 (Q3/6D). Document Type: Article.
Thibord F, Klarin D, Brody JA, Chen MH, Levin MG, Chasman DI, Goode EL, Hveem K, Teder M, Martinez-Perez A, Aissi D, Daian D, Ito K, Natarajan P, Lutsey PL, Nadkarni GN, de Vries PS, Cuellar G, Wolford BN, Pattee JW, Kooperberg C, Braekkan SK, Li RF, Saut N, Sept C, Germain M, Judy RL, Wiggins KL, Ko D, O’Donnell CJ, Taylor KD, Giulianini F, De Andrade M, et al. [Soria JM, Souto JC, Sabater M]. Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors. CIRCULATION. 2022; 146(16). DOI:10.1161/CIRCULATIONAHA.122.059675. PMID:36154123. IF:37,8 (Q1/1D). Document Type: Article.

Publications 2021

Anaya R, Rodriguez M, Gil JM, Vilalta N, Merchan A, Moral V, Mateo J, Martinez MJ. Correlation between PlateletWorks(R) and PFA-100(R) for Measuring Platelet Function before Urgent Surgery in Patients with Chronic Antiplatelet Therapy. Journal of Clinical Medicine. 2021; 10(2):255. DOI:10.3390/jcm10020255. PMID:33445597. IF:4,964.
Goumidi L, Thibord F, Wiggins KL, Li RF, Brown MR, Vlieg AV, Souto JC, Soria JM, Ibrahim M, Saut N, Daian D, Olaso R, Amouyel P, Debette S, Boland A, Bailly P, Morrison AC, Mook DO, Deleuze JF, Johnson A, de Vries PS, Sabater M, Chiaroni J, Smith NL, Rosendaal FR, Chasman DI, Tregouet DA, Morange PE. Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. BLOOD. 2021; 137(17). DOI:10.1182/blood.2020008997. PMID:33512453. IF:25,476.
Koller T, Kinast N, Castellanos AG, Garcia SP, Iglesias PP, Vintro XL, Arranz JM, Seto NV, Garcia MVM, Moreno AB, Aznar J, Albaladejo GE, Diaz M. Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry. Scandinavian Journal of Trauma Resuscitation & Emergency Medicine. 2021; 29(1):57. DOI:10.1186/s13049-021-00867-5. PMID:33836790. IF:3,803.
Llobet D, Vallve C, Tirado I, Vilalta N, Carrasco M, Oliver A, Mateo J, Fontcuberta J, Souto JC. Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project. BLOOD COAGULATION & FIBRINOLYSIS. 2021; 32(2). DOI:10.1097/MBC.0000000000001006. PMID:33337623. IF:1,061.
Mingot ME, Pardos J, Haya S, Bastida JM, Tassies D, Marco A, Nunez R, Garcia F, De Mora MCFS, Soto I, Alvarez MT, Asenjo S, Carrasco M, Lluch R, Martin JM, Rodriguez A, Rosello E, Torres L, Marcellini S, Moreto A, Rodriguez JA, Aguinaco R, Alonso N, Cervero C, Fernandez N, Martinez MP, Perez M, Perez R, Rodriguez R, Uribe M, Caparros IS, et al. Management of acquired hemophilia A: results from the Spanish registry. Blood Advances. 2021; 5(19). DOI:10.1182/bloodadvances.2021004626. PMID:34521101. IF:7,637.
Perez A, Batlle J, Pinto JC, Corrales I, Borras N, Garcia I, Cid AR, Bonanad S, Parra R, Mingot ME, Navarro N, Altisent C, Perez R, Moreto A, Herrero S, Soto I, Mosteirin NF, Jimenez V, Jacob AD, Fontanes E, Mateo J, Quismondo NC, Batlle F, Vidal F, Lopez MF. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project. HAEMOPHILIA. 2021; 27(6). DOI:10.1111/hae.14405. PMID:34494337. IF:4,263.
Roman M, Benitez O, Canaro MI, Fernandez MFL, Jaime FLJ, Arranz JM, Nunez R, Lopez MR, Aisa CS, Jimenez V. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. EXPERT OPINION ON BIOLOGICAL THERAPY. 2021; 21(9). DOI:10.1080/14712598.2021.1932811. PMID:34225551. IF:5,589.

CARDIOVASCULAR DISEASES

Thrombosis and Haemostasis

Main lines of research

Challenges

Group coordination

Members

Publications 2022

Publications 2021

Main lines of research

Challenges

Group coordination

Members

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau